Expanded labeling kits CellMosaic has recently launched a line of antibody and protein labeling kits powered by AqT linker technology and PerKit systems, offering a turnkey solution for customers to perform complex conjugations in-house. This presents a sales opportunity to target labs seeking faster, cost-effective labeling workflows and to upsell related AqT® technologies for advanced conjugation.

New product opportunities The company has introduced maleimide-activated protein carrier products and recently announced an Antibody Deruxtecan Kit, signaling a move into specialized conjugation reagents and payload-ready platforms. This creates cross-sell potential to customers building ADCs or protein-drug conjugates and to CROs needing ready-to-use components.

AqT technology focus AqT® and related technologies (AqueaTether®, oxLink™, sxLink™, NeIon™) drive drug conjugation, delivery, and analytical detection capabilities. Target customers include biotech R&D groups, pharma researchers, and assay developers seeking robust, site-specific conjugation methods and sensitive analytics.

Private collaborations CellMosaic has a track record of executing over 500 projects and delivering 300 unique conjugates via custom conjugation services, plus strategic partnerships such as the Biolinkk collaboration. This indicates a proven services ecosystem and opportunities to contract for bespoke conjugation work or co-development agreements.

Growth and reach With a revenue range of 1M–10M and recent product launches across labeling kits and ADC/PDC tools, CellMosaic appears positioned for accelerated growth. Prospects include expanding outreach to academic labs, contract research organizations, and mid-sized biotech firms seeking innovative conjugation and delivery solutions.